ArticleNature communications2025
Efficient mRNA delivery to resting T cells to reverse HIV latency.
Abstract read
In one paragraph
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Targeted delivery of mRNA to immune cells forDrug delivery · 2026Review
- Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles.Molecular therapy. Nucleic acids · 2026Article
- Advancements of mRNA-lipid nanoparticle links to gene editing and immune responses.Journal, genetic engineering & biotechnology · 2026Review
- Delivering the future of immunotherapy: A state-of-the-art review of gene editing in immune cells with lipid nanoparticles.Materials today. Bio · 2026Review
- Capsid-Targeting Biologic Achieves Broad HIV-1 Neutralization with a High Barrier to Resistance.International journal of molecular sciences · 2026Article
- What's Hot in HIV in 2025-A Basic and Translational Science Review From IDWeek 2025.The Journal of infectious diseases · 2026Review
- DNA-directed assembly of multivalent lipid nanoparticles for targeted T cell gene delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- AZD5582 robustly reactivates latently infected cells and clears the majority of those reactivated from the SIV reservoir.bioRxiv : the preprint server for biology · 2026Article
- Review
- Efficacy and Safety of Messenger RNA Vaccines.Health science reports · 2026Article
- Article
- Beyond Antiretroviral Therapy: Molecular and Immunological Innovations in HIV Treatment.Tropical medicine and infectious disease · 2026Review
- Bipolar CD4-targeted dual-DARPin-55/57 lipid nanoparticle enables efficient CRISPR/Cas-mediated HIV-1 DNA excision and reactivation blockade in latent CD4 T cell lines.Materials today. Bio · 2026Article
- Breaking into HIV-1's Epigenetic Vault: Cure Strategies to Eliminate the Viral Reservoir.Viruses · 2026Review
- Review
- TARDBP as a regulator of HIV-1 assembly and infection: a review of targeting the viral capsid precursor Pr55Gag and limiting viral core entry.Cell communication and signaling : CCS · 2026Review
- Selective reactivation of latent HIV using CyclinT1-Tat-containing virus-like particles.Virology · 2026Article
- Nanoparticles in HIV treatment for improved drug delivery, clinical translation, and future direction.Discover nano · 2026Review
- Research progress on HIV-1 structural proteins and antiviral therapies.Frontiers in immunology · 2026Review
- The effect of combining HIV latency reversal with inhibition of phosphoinositide-3 kinases or B-cell lymphoma-2 on the HIV reservoir.PLoS pathogens · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Paula M Cevaal *Department of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-4473-7904
Stanislav Kan *Department of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Bridget M Fisher *Department of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.ORCID http://orcid.org/0009-0008-8503-8150
Michael A Moso *Department of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-7948-3380
Abigail TanDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Haiyin LiuMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Abdalla AliDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Kiho TanakaDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-4821-801X
Rory A ShepherdDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.ORCID http://orcid.org/0009-0001-2215-2510
Youry KimDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Jesslyn OngDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Denzil L FurtadoDepartment of Chemical Engineering, The University of Melbourne, Parkville, VIC, Australia.
Marvin HolzDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Damian F J PurcellDepartment of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-4485-1726
Joshua M L CasanCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-4322-8561
Thomas PayneMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Wei ZhaoDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Mohamed FarehCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
James H McMahonDepartment of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-1460-5572
Steven G DeeksDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6371-747X
Rebecca HohDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Sushama TelwatteDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Colin W PoutonMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0003-0224-3308
Angus P R JohnstonMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0001-5611-4515
Frank CarusoDepartment of Chemical Engineering, The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-0197-497X
Jori SymonsTranslational Virology, Department of Medical Microbiology, University Medical Center, Utrecht, the Netherlands.ORCID http://orcid.org/0000-0001-6560-1577
Sharon R LewinDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. sharon.lewin@unimelb.edu.au.ORCID http://orcid.org/0000-0002-0330-8241
Michael RocheDepartment of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Funding
Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0MamfAR, The Foundation for AIDS Research (amfAR) 110406-73-RGRLDepartment of Health | National Health and Medical Research Council (NHMRC) 1135851Department of Health | National Health and Medical Research Council (NHMRC) 1149990Department of Health | National Health and Medical Research Council (NHMRC) 2026490NIAID NIH HHS UM1 AI164560U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (OER) 1UM1AI164560-01
Abstract
A major hurdle to curing HIV is the persistence of integrated proviruses in resting CD4
Indexed as
CD4-Positive T-LymphocytesHIV-1HIV InfectionsRNA, MessengerVirus LatencyHumansLipidsLiposomesNanoparticlestat Gene Products, Human Immunodeficiency VirusTranscription, GeneticLipid NanoparticlesLipidsLiposomesRNA, Messengertat Gene Products, Human Immunodeficiency Virus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.